Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro
Autor: | Uberto Pagotto, Eberhard Uhl, P. Lohrer, Günter K. Stalla, Ulrich Renner, U. Hopfner, Marco Losa, J. Gloddek |
---|---|
Rok vydání: | 2001 |
Předmět: |
Adenoma
Adult Male Vascular Endothelial Growth Factor A medicine.medical_specialty Angiogenesis Endocrinology Diabetes and Metabolism Rodentia Endothelial Growth Factors Biology Vascular endothelial growth inhibitor Dexamethasone Cellular and Molecular Neuroscience chemistry.chemical_compound Mice Endocrinology Internal medicine medicine Tumor Cells Cultured Animals Humans Growth factor receptor inhibitor Pituitary Neoplasms Aged Aged 80 and over Lymphokines Estradiol Neovascularization Pathologic Endocrine and Autonomic Systems Vascular Endothelial Growth Factors Neuropeptides Middle Aged Transforming Growth Factor alpha Rats Vascular endothelial growth factor B Vascular endothelial growth factor Vascular endothelial growth factor A Vascular endothelial growth factor C chemistry Pituitary Adenylate Cyclase-Activating Polypeptide Female Vascular endothelial growth factor production Somatostatin |
Zdroj: | Neuroendocrinology. 74(2) |
ISSN: | 0028-3835 |
Popis: | Angiogenesis, the formation of a new blood supply, is an essential step in tumorigenesis. Although vascular endothelial growth factor (VEGF) is known to be a very potent angiogenic factor in most solid tumors, little is known about its production and regulation in pituitary adenomas. We have investigated basal and stimulated VEGF production by rodent pituitary tumor cells (mouse corticotrope AtT20, rat lactosomatotrope GH3, mouse gonadotrope alpha T3-1 and mouse folliculostellate TtT/GF cells), and by hormone-inactive (27), corticotrope (9), lactotrope (3) and somatotrope (21) human pituitary adenoma cell cultures. All 4 pituitary cell lines secreted VEGF, which in the case of AtT20, GH3 and TtT/GF cells was inhibited by approximately 50% by dexamethasone. TtT/GF cells were the most responsive to the different stimuli used since basal values were augmented by pituitary adenylate cyclase activating polypeptide-38 (PACAP-38), interleukin-6 (IL-6), transforming growth factor-alpha (TGF-alpha), IGF-I and the somatostatin analogue ocreotide. However, in GH3, AtT20 and alpha T3-1 cells, basal VEGF levels where not enhanced with any of the stimuli tested. The majority of the human adenomas tested (92%) basally secreted measurable VEGF which was inhibited by dexamethasone in most cases (84%). VEGF levels were increased in hormone inactive adenomas, somatotrope tumors and prolactinomas by TGF-alpha, PACAP-38, and 17 beta-estradiol, respectively. In conclusion, pituitary tumor cells are capable of producing VEGF which may be involved in tumoral angiogenesis. Our results concerning the suppression of VEGF by dexamethasone suggest that glucocorticoids may have anti-angiogenic properties and therefore therapeutic relevance for the treatment of pituitary adenomas. |
Databáze: | OpenAIRE |
Externí odkaz: |